See more : Dalrada Financial Corporation (DFCO) Income Statement Analysis – Financial Results
Complete financial analysis of Novonesis (Novozymes) B (NSISBC.XD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novonesis (Novozymes) B, a leading company in the industry within the sector.
You may be interested
- Monstar Lab, Inc. (5255.T) Income Statement Analysis – Financial Results
- Fielmann Aktiengesellschaft (FLMNY) Income Statement Analysis – Financial Results
- Fredun Pharmaceuticals Limited (FREDUN.BO) Income Statement Analysis – Financial Results
- Business-intelligence of Oriental Nations Corporation Ltd. (300166.SZ) Income Statement Analysis – Financial Results
- Trelleborg AB (publ) (TREL-B.ST) Income Statement Analysis – Financial Results
Novonesis (Novozymes) B (NSISBC.XD)
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 17.90B | 17.55B | 14.95B | 14.01B | 14.37B |
| Cost of Revenue | 8.18B | 7.96B | 6.31B | 6.16B | 6.39B |
| Gross Profit | 9.72B | 9.59B | 8.64B | 7.85B | 7.99B |
| Gross Profit Ratio | 54.32% | 54.63% | 57.78% | 56.04% | 55.57% |
| Research & Development | 2.02B | 2.00B | 2.01B | 1.94B | 1.97B |
| General & Administrative | 959.00M | 952.00M | 859.00M | 739.00M | 827.00M |
| Selling & Marketing | 2.37B | 2.27B | 1.94B | 1.55B | 1.63B |
| SG&A | 3.33B | 3.20B | 2.83B | 2.30B | 2.46B |
| Other Expenses | 404.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.75B | 4.95B | 4.63B | 4.28B | 4.19B |
| Cost & Expenses | 13.92B | 12.91B | 10.94B | 10.44B | 10.58B |
| Interest Income | 83.00M | 84.00M | 84.00M | 53.00M | 4.00M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.17B | 1.24B | 1.17B | 1.04B | 996.00M |
| EBITDA | 5.63B | 5.72B | 5.06B | 4.70B | 4.58B |
| EBITDA Ratio | 31.47% | 32.59% | 33.85% | 33.54% | 31.89% |
| Operating Income | 3.98B | 4.48B | 3.89B | 3.66B | 3.59B |
| Operating Income Ratio | 22.21% | 25.53% | 26.05% | 26.14% | 24.96% |
| Total Other Income/Expenses | -67.00M | -5.00M | -83.00M | -142.00M | 211.00M |
| Income Before Tax | 3.91B | 4.56B | 3.92B | 3.52B | 3.80B |
| Income Before Tax Ratio | 21.84% | 25.96% | 26.25% | 25.13% | 26.43% |
| Income Tax Expense | 870.00M | 870.00M | 779.00M | 695.00M | 644.00M |
| Net Income | 3.02B | 3.68B | 3.15B | 2.83B | 3.15B |
| Net Income Ratio | 16.89% | 20.94% | 21.04% | 20.16% | 21.94% |
| EPS | 10.88 | 13.19 | 11.23 | 10.02 | 11.01 |
| EPS Diluted | 10.88 | 13.19 | 11.23 | 10.02 | 11.01 |
| Weighted Avg Shares Out | 277.94M | 278.70M | 280.14M | 281.94M | 286.47M |
| Weighted Avg Shares Out (Dil) | 277.87M | 278.73M | 280.23M | 282.02M | 286.55M |
No news found for: NSISBC.XD
Source: https://incomestatements.info
Category: Stock Reports